Project Orbis News Today

More than 234,000 new cases of lung cancer are expected to be diagnosed in the US this year

Alectinib approved by US FDA for auxiliary treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who underwent tumor resection.

​​​​​​​On April 5, the FDA granted accelerated approval to AstraZeneca and Daiichi Sankyo’s ENHERTU (trastuzumab deruxtecan) for adult patients with unresectable or metastatic...

AstraZeneca plc and Daiichi Sankyo's Enhertu has gained US approval for treating HER2-positive solid tumours, marking a significant advancement in cancer treatment.

Press Release ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Apr 5, 2024--

Based on three Phase II trials of AstraZeneca and Daiichi Sankyos Enhertu which showed clinically meaningful responses across a broad range of tumours ...

FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.

/PRNewswire/ -- Servier, a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves, today announced the FDA...

AstraZeneca's Tagrisso approved in the US for EGFRm non-small cell lung cancer with chemotherapy. FLAURA2 trial results show significant benefit.